- Home
- CMC vs ADMA Comparison
CMC vs ADMA Comparison
Compare CMC & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMC
- ADMA
- Stock Information
- Founded
- CMC 1915
- ADMA 2004
- Country
- CMC United States
- ADMA United States
- Employees
- CMC N/A
- ADMA N/A
- Industry
- CMC Steel/Iron Ore
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMC Industrials
- ADMA Health Care
- Exchange
- CMC Nasdaq
- ADMA Nasdaq
- Market Cap
- CMC 5.5B
- ADMA 5.1B
- IPO Year
- CMC 1987
- ADMA N/A
- Fundamental
- Price
- CMC $48.68
- ADMA $17.74
- Analyst Decision
- CMC Buy
- ADMA Strong Buy
- Analyst Count
- CMC 8
- ADMA 4
- Target Price
- CMC $59.14
- ADMA $24.25
- AVG Volume (30 Days)
- CMC 1.0M
- ADMA 2.7M
- Earning Date
- CMC 06-23-2025
- ADMA 08-07-2025
- Dividend Yield
- CMC 1.48%
- ADMA N/A
- EPS Growth
- CMC N/A
- ADMA N/A
- EPS
- CMC 0.63
- ADMA 0.84
- Revenue
- CMC $7,738,612,000.00
- ADMA $459,381,000.00
- Revenue This Year
- CMC N/A
- ADMA $23.35
- Revenue Next Year
- CMC $8.14
- ADMA $27.67
- P/E Ratio
- CMC $76.92
- ADMA $21.27
- Revenue Growth
- CMC N/A
- ADMA 62.23
- 52 Week Low
- CMC $37.92
- ADMA $10.21
- 52 Week High
- CMC $64.53
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- CMC 53.41
- ADMA 32.83
- Support Level
- CMC $47.92
- ADMA $20.42
- Resistance Level
- CMC $49.95
- ADMA $22.37
- Average True Range (ATR)
- CMC 1.23
- ADMA 0.88
- MACD
- CMC -0.16
- ADMA -0.28
- Stochastic Oscillator
- CMC 23.72
- ADMA 1.07
About CMC Commercial Metals Company
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.